Mild/minimal stimulation protocol for ovarian stimulation of patients at high risk of developing ovarian hyperstimulation syndrome

Journal of Endocrinological Investigation

Volumn 37, Issue 1, 2014, Pages 65-70

  Rinaldi, L ^a   Lisi, F ^b   Selman, H ^a  

^a RISEL One Day Medical Center   (Italy)

^b Biogenesi Villa Europa Clinic and Sterility and Fertility Unit   (Italy)

Author keywords

Follicle stimulating hormone; GnRH agonist; GnRH antagonist; OHSS; Ovarian stimulation; Pregnancy

Indexed keywords

GONADORELIN ANTAGONIST; RECOMBINANT FOLLITROPIN;

ADULT; ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL PROTOCOL; COMPARATIVE STUDY; CONTROLLED STUDY; DELIVERY; DOWN REGULATION; FEMALE; FEMALE INFERTILITY; FERTILIZATION IN VITRO; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; METAPHASE; MILD OVARIAN STIMULATION; OOCYTE; OOCYTE CLEAVAGE; OOCYTE RETRIEVAL; OPEN STUDY; OVARY HYPERSTIMULATION; PATIENT SAFETY; PREGNANCY RATE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STANDARD; STIMULATION;

ADULT; FEMALE; FOLLICLE STIMULATING HORMONE; FOLLICLE STIMULATING HORMONE, HUMAN; GONADOTROPIN-RELEASING HORMONE; HUMANS; OVARIAN HYPERSTIMULATION SYNDROME; OVULATION INDUCTION; PREGNANCY; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS;

EID: 84900548052     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.1007/s40618-013-0021-1     Document Type: Article

References (53)

1. Templeton A, Morris JK (1998) Reducing the risk of multiple births by transfer of two embryos after in vitro fertilization. N Engl J Med 339:573-577 (Pubitemid 28385653)
2. Macklon NS, Stouffer RL, Giudice LC, Fauser BC (2006) The science behind 25 years of ovarian stimulation for in vitro fertilization. Endocr Rev 27:170-207
3. Fauser BC, Devroey P (2005) Why is the clinical acceptance of gonadotropin-releasing hormone antagonist cotreatment during ovarian hyperstimulation for in vitro fertilization so slow? Fertil Steril 83:1607-1611 (Pubitemid 40834230)
4. Wang YA, Sullivan EA, Black D, Dean J, Bryant J, Chapman M (2005) Preterm birth and low birth weight after assisted reproductive technology-related pregnancy in Australia between 1996 and 2000. Fertil Steril 83:1650-1658 (Pubitemid 40824795)
5. Navot D, Bergh PA, Laufer N (1992) Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. Fertil Steril 58:249-261
6. Golan A, Ron-El R, Soffer Y, Weinraub Z, Caspi E (1989) Ovarian hyperstimulation syndrome: an update review. Obstet Gynecol Surv 44:430-440 (Pubitemid 19138981)
7. Smitz J, Camus M, Devroey P, Erard P, Wisanto A, Van Steirteghem AC (1990) Incidence of severe ovarian hyperstimulation syndrome after GnRH agonist/HMG superovulation for in vitro fertilization. Hum Reprod 5:993-997
8. Schenker JG, Weinstein D (1978) Ovarian hyperstimulation syndrome: a current survey. Fertil Steril 30:255-268 (Pubitemid 8397513)
9. Aboulghar MA, Mansour RT, Serour GI et al (1992) Follicular aspiration does not protect against the development of ovarian hyperstimulation syndrome. J Assist Reprod Genet 9:238-243
10. Delvigne A, Dubois M, Battheu B et al (1993) The ovarian hyperstimulation syndrome in in vitro fertilization: a Belgian multicentric study. II. Multiple discriminant analysis for risk prediction. Hum Reprod 8:1361-1366 (Pubitemid 23265962)
11. Ragni G, Vegetti W, Riccaboni A, Engl B, Brigante C, Crosignani PG (2005) Comparison of GnRH agonists and antagonists in assisted reproduction cycles of patients at high risk of ovarian hyperstimulation syndrome. Hum Reprod 20:2421-2425 (Pubitemid 41222487)
12. Ferraretti AP, Gianaroli L, Magli C, Fortini D, Selman HA, Feliciani E (1999) Elective cryopreservation of all pronucleate embryos in women at risk of ovarian hyperstimulation syndrome: efficiency and safety. Hum Reprod 14:1457-1460 (Pubitemid 29265433)
13. Gianaroli L, Ferraretti AP, Fiorentino A (1996) The ovarian hyperstimulation syndrome. Reprod Med Rev 5:169-184 (Pubitemid 27244129)
14. Gonen Y, Balakier H, Powel W, Casper RF (1990) Use of gonadotrophin releasing hormone agonist to trigger follicular maturation for in vitro fertilization. J Clin Endocrinol Metab 71:918-922
15. Tomazevic T, Meden-Vrtovec H (1996) Early timed follicular aspiration prevents severe ovarian hyperstimulation syndrome. J Assist Reprod Genet 13:282-286 (Pubitemid 26104586)
16. Koenig E, Bussen S, Suetterlin M, Stteck T (1998) Prophylactic intravenous hydroxylethyl starch solution prevents moderatesevere ovarian hyperstimulation in in vitro fertilization patients: a prospective randomized, doubleblind and placebo-controlled study. Hum Reprod 13:2421-2424 (Pubitemid 28451217)
17. Edwards RG, Lobo R, Bouchard P (1996) Time to revolutionize ovarian stimulation. Hum Reprod 11:917-919
18. Edwards B (2007) IVF, IVM, natural cycle IVF, minimal stimulation IVF-time for a rethink. RBM online 15:106-119
19. Nargund G, Fauser BCJM, Macklon NS, Ombelet W, Nygren K, Frydman R (2007) For the Rotterdam ISMAAR consensus group on terminology for ovarian stimulation for IVF: the ISMAAR proposal on terminology for ovarian stimulation for IVF. Hum Reprod 22:2801-2804
20. Tozer AJ, Iles RK, Iammarrone E, Gillott CM, Al-Shawaf T, Grudzinskas JG (2004) The effects of 'coasting' on follicular fluid concentrations of vascular endothelial growth factor in women at risk of developing ovarian hyperstimulation syndrome. Hum Reprod 19:522-528 (Pubitemid 38344510)
21. Chen C-D, Chao KH, Yang J-H (2003) Comparison of coasting and intravenous albumin in the prevention of ovarian hyperstimulation syndrome. Fertil Steril 80:86-90 (Pubitemid 36808860)
22. YoussefMA, Van der Veen F, Al-Inany HG, Griesinger G,Mochtar MH, van Wely M (2011) Gonadotropin-releasing hormone agonist versus hCG for oocyte triggering in antagonist assisted reproductive technology cycles. Cochrane Database Syst Rev 1:CD008046
23. Kol S, Itskovitz-Eldor J (2010) Gonadotropin-releasing hormone agonist trigger: the way to eliminate ovarian hyperstimulation syndrome-a 20-year experience. Semin Reprod Med 28:500-505
24. Kol S, Humaidan P (2013) GnRH agonist triggering: recent developments. Reprod Biomed Online 26:226-230
25. Youssef MA, van Wely M, Hassan MA et al (2010) Can dopamine agonists reduce the incidence and severity of OHSS in IVF/ ICSI treatment cycles? a systematic review and meta-analysis. Hum Reprod Update 16:459-466
26. Whelan JG, Vlahos NF (2000) The ovarian hyperstimulation syndrome. Fertil Steril 73(883-89):6
27. Ulug U, Bahceci M, Erden HF, Shalev E, Ben-Shlomo I (2002) The significance of coasting duration during ovarian stimulation for conception in assisted fertilization cycles. Hum Reprod 17:310-313 (Pubitemid 34168432)
28. Blondin P, Guilbault LA, Sirard MA (1997) The time interval between FSH-P administration and slaughter can influence the developmental competence of beef heifer oocytes. Theriogenology 48:803-813 (Pubitemid 28135496)
29. Krasnow JS, Berga SL, Guzick DS, Zeleznik AJ, Yeo KT (1996) Vascular permeability factor and vascular endothelial growth factor in ovarian hyperstimulation: a preliminary report. Fert Steril 65:552-555 (Pubitemid 26069111)
30. Fluker MR, Copeland JE, Yuzpe AA (2000) An ounce of prevention: outpatient management of the ovarian hyperstimulation syndrome. Fertil Steril 73:821-824 (Pubitemid 30154125)
31. Carizza C, Abdelmassih V, Abdelmassih S et al (2008) Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: a prospective randomized study. Reprod Biomed Online 17:751-755
32. Tehraninejad ES, Hafezi M, Arabipoor A, Aziminekoo E, Chehrazi M, Bahmanabadi A (2010) Comparison of cabergoline and intravenous albumin in the prevention of ovarian hyperstimulation syndrome: a randomized clinical trial. J Assist Reprod Genet 29:259-264
33. Gómez R, Soares SR, Busso C, Garcia-Velasco JA, Simón C, Pellicer A (2010) Physiology andpathology of ovarian hyperstimulation syndrome. Semin Reprod Med 28:448-457
34. Aboulghar M, Evers JH, Al-Inany H (2002) Intravenous albumin for preventing severe ovarian hyperstimulation syndrome: a Cochrane review. Hum Reprod 17:3027-3032 (Pubitemid 35469247)
35. Jee BC, Suh CS, Kim YB, Kim SH, Choi YM, Kim JG, Moon SY (2010) Administration of intravenous albumin around the time of oocyte retrieval reduces pregnancy rate without preventing ovarian hyperstimulation syndrome: a systematic review and meta-analysis. Gynecol Obstet Invest 70:47-54
36. Youssef MA, Al-Inany HG, Evers JL, Aboulghar M (2011) Intravenous fluids for the prevention of severe ovarian hyperstimulation syndrome. Cochrane Database Syst Rev 2:CD001302
37. Devroey P, Bourgain C, Macklon NS, Fauser BC (2004) Reproductive biology and IVF: ovarian stimulation and endometrial receptivity. Trends Endocrinol Metab 15:84-90 (Pubitemid 38258332)
38. Beckers NG, Platteau P, Eijkemans MJ et al (2006) The early luteal phase administration of oestrogen and progesterone does not induce premature luteolysis in normo-ovulatory women. Eur J Endocrinol 155:355-363 (Pubitemid 44274711)
39. Baart EB, Martini E, Eijkemans MJ et al (2007) Milder ovarian stimulation for in vitro fertilization reduces aneuploidy in the human preimplantation embryo: a randomized controlled trial. Hum Reprod 22:980-988
40. Westergaard LG, Erb K, Laursen S, Rasmussen PE, Rex S (1996) The effect of human menopausal gonadotropin and highly purified, urine-derived follicle stimulating hormone on the outcome of in vitro fertilisation in down regulated normogonadotropic women. Hum Reprod 11:1209-1213 (Pubitemid 26245316)
41. Westergaard LG, Laurse SB, Anderson CY (2000) Increased risk of early pregnancy loss by profound suppression on luteinizing hormone during ovarian stimulation in normogonadotrophic women undergoing assisted reproduction. Hum Reprod 15:1003-1008 (Pubitemid 30251290)
42. Fleming R, Lloyd F, Herbert M, Fenwick J, Griffiths T, Murdoch A (1998) Effects of profound suppression of luteinizing hormone during ovarian stimulation on follicular activity, oocyte and embryo function in cycles stimulated with purified follicle stimulating hormone. Hum Reprod 13:1788-1792
43. Janssens RMJ, Lambalk CB, Vermiden JPW et al (2000) Dosefinding study of triptorelin acetate for prevention of a premature LH surge in IVF: a prospective, randomised, double-blind pla-cebo- controlled study. Hum Reprod 15:2333-2340
44. Cedrin-Durnerin I (2004) Antagonist protocols: residual LH levels and the value of exogenous LH supplementation. J Gynecol Obstet Biol Reprod (Paris) 33:3S29-3S31
45. Urman B, Fluker MR, Yuen BH, Fleige-Zahradka BG, Zouves CG, Moon YS (1992) The outcome of in vitro fertilization and embryo transfer in women with polycystic ovary syndrome failing to conceive after ovulation induction with exogenous gonadotropins. Fertil Steril 57:1269-1273
46. Homburg R, Berkowitz D, Levy T, Feldberg D, Ashkenazi J, Ben-Rafael Z (1993) In vitro fertilization and embryo transfer for the treatment of infertility associated with polycystic ovary syndrome. Fertil Steril 60:858-863 (Pubitemid 23324775)
47. Doldi N, Marsiglio E, Destefani A, Gessi A, Merati G, Ferrari A (1999) Elevated serum progesterone on the day of hCG administration in IVF is associated with a higher pregnancy rate in polycystic ovary syndrome. Hum Reprod 14:601-605 (Pubitemid 29131232)
48. Kodama H, Fukuda J, Karube H, Matsui T, Shimizu Y, Tanaka T (1995) High incidence of embryo transfer cancellations in patients with polycystic ovarian syndrome. Hum Reprod 10:1962-1967
49. Marci R, Senn A, Dessole S, Chanson A, Loumaye E, Grandi P, Germond M (2001) A low-dose stimulation protocol using highly purified follicle-stimulating hormone can lead to high pregnancy rates in in vitro fertilization patients with polycystic ovaries who are at risk of a high ovarian response to gonadotropins. Fertil Steril 75:1131-1135 (Pubitemid 32522609)
50. Sundstrom P, Nilsson BO (1988) Meiotic and cytoplasmic maturation of oocytes collected in stimulated cycles is asynchronous. Hum Reprod 3:613-619
51. Moor RM, Osborn JC, Crosby IM (1985) Gonadotrophin-induced abnormalities in sheep oocytes after superovulation. J Reprod Fertil 74:167-172 (Pubitemid 15010384)
52. Tesarik J, Mendoza C (1995) Nongenomic effects of 17b-estradiol on maturing human oocytes: relationship to oocyte developmental potential. J Clin. Endocrino Metab 80:1438-1443
53. Tesarik J, Mendoza C (1997) Direct non-genomic effects of follicular steroids on maturing human oocytes: oestrogen versus androgen antagonism. Hum Reprod Update 3:95-100 (Pubitemid 27389981)